



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Jens Sonksen

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-01-2009	01-01-2012	Astra Zeneca	Saracatinib	prostate cancer
Past	01-04-2014	01-02-2016	Grünenthal	cebranopadol	cancer pain
Past	01-03-2011	01-05-2018	Medivation/Astellas	enzalutamide	prostate cancer
Past	01-03-2017	01-05-2018	Janssen	niraparib	prostate cancer
Past	01-01-2013	01-02-2014	Orexo	alfentanil	pain control during prostate biopsy
Past	01-09-2012	01-11-2016	Neotract	urolift implants	benign prostate hypertrofia
Past	01-10-2015	01-10-2018	GT Urologicals	relief device	artificial urethral sphincter
Current	01-03-	22-03-	Medivation/Pfizer	enzalutamide	prostate cancer

	2014	2023			
Current	01-11-2016	22-03-2023	Astellas	enzalutamide	prostate cancer
Current	01-09-2011	22-03-2023	Astellas	enzalutamide	prostate cancer
Current	01-04-2021	22-03-2023	Janssen	Apalutamid	Prostate cancer
Past	01-01-2010	01-01-2018	Ferring	GnRH antagonist versus GnRH agonist	prostate cancer
Past	01-11-2012	01-05-2013	Astellas	ASP3652	bladder pain syndrome/interstitial cysti
Past	01-04-2015	01-10-2016	Auxillium	Xiaflex	peyronies disease
Past	01-08-2017	01-09-2018	Aquinox	AQX_1125	bladder pain syndrome/interstitial cysti
Past	01-09-2015	01-09-2019	Astellas	enzalutamide	prostate cancer
Past	01-09-2017	01-01-2020	Myovant	relugolix	prostate cancer
Past	01-11-2019	01-08-2022	Rhovac	rhovac_002	prostate cancer
Past	01-06-2022	01-07-2022	Hinova Pharmceuitcal	HC1119	Prostate cancer
Past	01-03-2012	01-10-2015	Astellas	enzalutamide	prostate cancer
Past	01-01-2014	01-02-2018	Bavarian Nordic	prostavac_V/F +/- GM_CSF	prostate cancer

1.7 Grant / Funding to organisation /institution

No interest declared

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

I am a stockholder in Multicept A/S (medical devices). Annual Financial Assessment European Medicines Agency Royalties EAU scientific journal: 13.55%, 50% non_industry ? 50% industry Results EAU meetings: 77.18%, 50% non_industry, 50% industry Membership fees: 6.35%, 100% non_industry Educational grants: 1.46%, 100% industry Other educational products and services: 1.46%, 100% non_industry Overall proportion of industry and non_industry: 39.87 vs 60.13% Funding Resources: The following pharmaceutical companies provide funding to EAU: Astellas Pharma Europe Ltd Ipsen Innovation Cook Medical Europe Ltd. Olympus Europa SE & Co. KG Intuitive Surgical Sarl Janssen Pharmaceutica NV Karl Storz GmbH & Co. KG GlaxoSmithKline Services Unlimited Merck sharp & Dohme Corp. Recordati Industria Chimica e farmaceutica S.p.A. Ferring International Center S.A. Bristol_Myers Squibb The highest contribution from a single company is less than 6% of the organisation's total income.

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Jens Sonksen
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.